Nexien BioPharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXEN research report →
Companywww.nexienbiopharma.com
Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders.
- CEO
- Richard S. Greenberg
- IPO
- 2017
- HQ
- Glendale, CO, US
Price Chart
Valuation
- Market Cap
- $7.08K
- P/E
- -0.10
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 51.01%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-239,000 · 33.98%
- EPS
- $-0.00 · 37.93%
- Op Income
- $-156,000
- FCF YoY
- 21.27%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.85
- Avg Volume
- 5.61K
Get TickerSpark's AI analysis on NXEN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 23, 24 | Greenberg Richard S | other | 1,000,000 |
| May 23, 24 | Wasoff Evan L | other | 2,000,000 |
| Oct 31, 23 | Greenberg Richard S | other | 250,000 |
| Oct 31, 23 | Wasoff Evan L | other | 250,000 |
| Jul 25, 23 | Goldfarb Robert I | other | 250,000 |
| Apr 1, 23 | Goldfarb Robert I | other | 250,000 |
| Aug 19, 20 | Goldfarb Robert I | other | 1,000,000 |
| Jul 25, 23 | Greenberg Richard S | other | 250,000 |
| Jul 25, 23 | Wasoff Evan L | other | 250,000 |
| Apr 1, 23 | Wasoff Evan L | other | 250,000 |
Our NXEN Coverage
We haven't published any research on NXEN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NXEN Report →